PB 3 of 2021

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 1)

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health make the following determination.

Dated 27 January 2021

THEA CONNOLLY
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health

Contents

1 Name

(1) This instrument is the *National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 1)*.

(2) This instrument may also be cited as PB 3 of 2021.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information

Column 1	Column 2	Column 3
Provisions	**Commencement**	**Date/Details**
1. *The whole of this instrument*	*1 February 2021.*	

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 89A(3) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

[1] Schedule 1, after entry for Fluoxetine in the form Capsule 20 mg (as hydrochloride)

insert:

	Capsule 20 mg (as hydrochloride) (USP)	Oral

[2] Schedule 1, entry for Ocriplasmin

omit:

	Solution concentrate for intravitreal injection 0.5 mg in 0.2 mL	Injection

[3] Schedule 1, after entry for Phenelzine in the form Tablet 15 mg (as sulfate)

insert:

	Tablet 15 mg (as sulfate) (USP)	Oral

[4] Schedule 1, after entry for Terbutaline in the form Powder for oral inhalation in breath actuated device containing terbutaline sulfate 500 micrograms per dose, 100 doses

insert:

	Powder for oral inhalation in breath actuated device containing terbutaline sulfate 500 micrograms per dose, 120 doses	Inhalation by mouth

[5] Schedule 1, after entry for Trihexyphenidyl in the form Tablet containing trihexyphenidyl hydrochloride 2 mg

insert:

	Tablet containing trihexyphenidyl hydrochloride 2 mg (USP)	Oral